GoldenGolden
Advanced Search
RiverVest Venture Partners

RiverVest Venture Partners

RiverVest Venture Partners invests in early-stage life science companies.

RiverVest Venture Partners focuses exclusively on innovations in life sciences, a field in which their team has significant research, clinical, operational and investment expertise. The team's deep domain experience allows them to identify promising investment opportunities, particularly in biopharmaceuticals and medical devices. They provide practical advice and strategic leadership to help entrepreneurs drive early-stage companies forward. RiverVest founds and actively incubates life science companies, including through its Archer Seed Fund. The Firm also invests in select later-stage opportunities to diversify risk and maximize portfolio returns. In every case, it takes a hands-on investment approach, preferring to be represented on the boards of their portfolio companies.

Investment

RiverVest Venture Partners' investments include Excaliard Pharmaceuticals, Cabrellis Pharmaceuticals, MacroGenics, Kereos, Velocimed, Auxeris Therapeutics, Salient Surgical Technologies and NexRay.

Their exited investments include Allakos, Mirum Pharmaceuticals, ZS Pharma, Otonomy, MacroGenics, Accumetrics, Lumena Pharmaceuticals, IDEV Technologies, Securus Medical Group and Lutonix.

Timeline

Associated investment funds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Ben Adams
March 25, 2021
FierceBiotech
Venture capitalist firm RiverVest Venture Partners has closed its fifth fund with a $275 million raise, bumping up its total over the years to a meaty $1.6 billion.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.